AFMD:NSD-Affimed N.V (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.04

Change

0.00 (0.00)%

Market Cap

USD 0.96B

Volume

1.19M

Average Target Price

USD 14.75 (+83.46%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD79.98B 133.51 104.16
REGN Regeneron Pharmaceuticals, Inc

N/A

USD57.31B 15.31 11.96
BNTX BioNTech SE

N/A

USD51.30B -99,999.99 31.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.63B 17.91 12.34
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.06B 58.65 41.96
BGNE BeiGene, Ltd

N/A

USD29.61B N/A N/A
SGEN Seagen Inc

N/A

USD28.37B 43.61 39.21
GMAB Genmab A/S

N/A

USD28.05B 26.59 3.73
RPRX Royalty Pharma plc

N/A

USD26.73B 22.60 15.75
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD20.79B N/A N/A

ETFs Containing AFMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.14% 79% C+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.14% 79% C+ 81% B-
Trailing 12 Months  
Capital Gain 107.22% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.22% 85% B 83% B
Trailing 5 Years  
Capital Gain 173.47% 76% C 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.47% 76% C 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 46.13% 74% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.13% 74% C 84% B
Risk Return Profile  
Volatility (Standard Deviation) 94.65% 30% F 17% F
Risk Adjusted Return 48.73% 74% C 68% D+
Market Capitalization 0.96B 71% C- 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.98 15% F 13% F
Price / Cash Flow Ratio -49.30 92% A- 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -74.76% 36% F 14% F
Return on Invested Capital -61.25% 39% F 13% F
Return on Assets -15.12% 74% C 22% F
Debt to Equity Ratio 0.32% 81% B- 91% A-
Technical Ratios  
Short Ratio 3.40 63% D 46% F
Short Percent 5.11% 63% D 38% F
Beta 2.72 4% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector